Login to Your Account

Vivus Skyrockets

Stock Frenzy After Surprisingly Positive EMDAC Vote on Qnexa

By Catherine Shaffer
Staff Writer

Friday, February 24, 2012

Shares of Vivus Inc. surged 77.5 percent Thursday following an overwhelmingly positive vote by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee for its weight loss candidate Qnexa (phentermine/topiramate). (See BioWorld Today, Feb. 23, 2012.)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription